youtube_live
Q2 2027 earnings • released • Revenue beat +1.47%
See resultschevron_right
4547:TYO
Kissei Pharmaceutical Co Ltd
Â¥4,400.00
arrow_upward
+12.53%(+490.00) 1D
Nov 17, 3:30:00 PM GMT+9 · JPY
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 4547...
Open
Â¥4,040
High
Â¥4,400
Low
Â¥4,010
Mkt. cap
204.78B
Avg. vol.
82.43K
Volume
544.20K
Dividend
2.84%
Quarterly dividend
Â¥31
Ex-dividend date
Mar 30, 2027
P/E ratio
16.31
52-wk high
Â¥5,040
52-wk low
Â¥3,500
EPS
Â¥270
Shares outstanding
46.72M
No. of employees
2K
Open
Â¥4,040
High
Â¥4,400
Low
Â¥4,010
Mkt. cap
204.78B
Avg. vol.
82.43K
Volume
544.20K
Dividend
2.84%
Quarterly dividend
Â¥31
Ex-dividend date
Mar 30, 2027
P/E ratio
16.31
52-wk high
Â¥5,040
52-wk low
Â¥3,500
EPS
Â¥270
Shares outstanding
46.72M
No. of employees
2K
News stories
From web sources and news partners
ChartMill
·
46 minutes ago
S&P 500 Losers: Software Stocks Lead Session Declines
Fox Business
·
1 hour ago
S&P 500 decline driven by semiconductor confidence issues, says Scott Chronert
MarketWatch
·
36 minutes ago
Only two ‘Magnificent Seven’ stocks have managed to beat the S&P 500 since the start of 2025
Traders Union
·
1 hour ago
Bitcoin-to-S&P 500 ratio holds trendline support, James Van Straten notes
Profile
Kissei Pharmaceutical is a pharmaceutical company based in Matsumoto, Nagano, Japan. Products discovered or developed by Kissei include:
Difelikefalin
Fostamatinib
Linzagolix
Mitiglinide
Remogliflozin etabonate
Silodosin
Tranilast
In March 2020, Kissei and CG Oncology, Inc. announced an exclusive license, development, and commercialization agreement for CG's oncolytic immunotherapy drug CG0070. The agreement covered Japan, South Korea, Taiwan, and other Asian countries, but not China. Wikipedia
About Kissei Pharmaceutical Co Ltd
CEOMutsuo Kanzawa
Employees1.79K
FoundedAug 9, 1946
HeadquartersMatsumoto, Nagano, Japan
SectorHealth Care
IndustryPharmaceutical industry
Websitekissei.co.jp